Abstract
Background and Purpose EVT is a standard treatment for LVO in patients with an NIHSS score ≥6, but its role in mild stroke (NIHSS <6) remains uncertain. This study aims to explore the association between EVT and clinical outcomes in mild stroke.
Methods This non-randomized cohort study prospectively enrolled consecutive mild stroke patients at 35 comprehensive stroke centers across 15 Chinese provinces from January 2020 to December 2023. Patients were categorized into pEVT or BMM groups, including those who received rEVT after deterioration. The primary outcome was an excellent outcome (mRS score of 0-1) at 90 days. Secondary outcomes included a good outcome (mRS score of 0-2) and mRS shift. Safety endpoints were mortality and sICH. Outcomes were compared between groups using multivariable logistic regression and IPTW.
Results Finally, 307 patients were included. 110 received pEVT, and 190 received BMM. In the IPTW model, the pEVT group had higher rates of excellent (aOR=3.6, 95%CI=2.5-5.2) and good (aOR=4.0, 95%CI=2.5-5.6) outcomes, lower mortality (aOR=0.1, 95%CI=0.01-0.4), and a better 90-day mRS shift (aOR=0.2, 95%CI=0.1-0.3,), with similar sICH rates. Among the BMM group, 80 patients (42.1%) experienced early neurological deterioration (END), with 55 receiving rEVT. In the multivariable model, the pEVT group had higher rates of excellent (aOR=7.2, 95%CI=1.4-37.9) and good (aOR=4.1, 95%CI=1.2-14.8) outcomes and a better mRS shift (aOR=2.0, 95%CI=0.9-4.8).
Conclusions Primary EVT significantly increases the likelihood of achieving an excellent outcome in mild stroke. Over 40% of mild stroke patients treated with BMM experienced END, and rEVT effectively improved the prognosis.
Question What is the optimal strategy for mild stroke with LVO?
Findings This national prospective registry study demonstrated that pEVT significantly improved the prognosis of mild stroke patients with LVO compared to BMM. Approximately 40% of patients in the BMM group experienced END, and rEVT increased the likelihood of an excellent outcome in these patients.
Meaning Primary EVT can significantly increase the probability of an excellent outcome in patients with mild stroke and LVO. Over 40% of patients with mild stroke treated with BMM experienced END, and rEVT effectively improved their prognosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Wenhuo Chen received grants from the Natural Science Foundation of Fujian Province (Grant No. 2022J01123162) and Dr. Tingyu Yi received grants from Beijing Health Promotion Association (Grant No. BHPA2021IN002) and National Health Commission Capacity Building and Continuing Education Center (Grant No. GWJJ20221003).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the ethics committee of Zhangzhou Municipal Hospital, Fujian Medical University, China, and each subcenter. All patients or their legally authorized representatives provided signed, informed consent forms.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos